Serum S100A12 Levels Are Correlated With The Presence And Severity Of Coronary Artery Disease In Patients With Type 2 Diabetes Mellitus

Background The risk of cardiovascular disease mortality in patients with T2 DM is more than twice that of age-matched subjects. Growing evidence also supports that diabetic patients have increased risks of impaired endothelial function and inflammation responses that lead to atherosclerotic cardiovascular disease. Therefore,an early evaluation of the risks for coronary artery disease(CAD) may help to improve prognosis by managing and minimizing the risk factors in diabetic patients without delay. Noninvasive blood biomarkers rep- resent appropriate alternatives for diagnosing and stratifying the risk of disease at its earliest stage.S100A12, also known as an extracellular newly identified receptor for advanced glycation end-products(ENRAGE)-binding protein,is a member of the S100 family of calcium-binding proteins predominantly expressed and secreted by granulocytes. Recently,there has been an increasing interest in the role of S100A12 as an indicator of inflammation. Serum S100A12 concentrations elevated significantly in anumber of inflammatory disorders such as inflammatory bowel disease,rheumatoid arthritis,and glomerulonephritis. The best-known target protein of S100A12 is the receptor for advanced glycation end- products(RAGE). After binding with RAGE, S100A12 induces the production of proinflammatory cytokines and increases expression of adhesion molecules, which might play a crucial role in the development of diabetes and accelerated atherosclerosis.Despite the large interest in the(patho-)physiological properties of S100A12 in diabetes and atherosclerosis, information regarding the relationship between S100A12 and CAD in patients with T2 DM is still limited. Therefore, the present study aimed to investigate the correlation of serum S100A12 levels with the presence and severity of CAD in patients with T2 DM.Purpose In this study, we demonstrated on the relationship between the occurrency and severity of CAD and the serum levels of S100A12 in the patients with type 2 diabetes. By understanding the effect of S100A12 in type 2 diabetes patients with CAD, further analyze the correlation between S100A12, hs-CRP levels and severity of CAD in type 2 diabetes patients. Subsequencely explore the possibility of S100A12 to be a novel biomarker for predicting the occurrency and development of CAD in T2 DM patients.Methods According to the coronary angiography, 188 type 2 diabetes patients were divided into non-CAD diabetic group(T2DM-non-CAD)(n=103) and CAD diabetic group(T2DM-CAD)(n = 85). And another 51 healthy adults were involved for control group. Coronary atherosclerosis index(CAI). S100A12 serum levels using ELISA assay. All data were processed using SPSS 17.0 software(SPSS Inc, Chicago, IL).Results Serum S100A12 levels were significantly higher in patients with T2 DM with CAD than in those without CAD. Multivariate logistic regression analysis revealed that serum S100A12 levels were independently associated with the presence of CAD. SerumS100A12 levels were positively correlated with the Coronary Atherosclerosis Index scores after adjusting for other clinical characteristics.Conclusions High S100A12 levels are associated with the presence and severity of CAD in patients with T2 DM. S100A12 may become novel biomarkers to predict the development of CAD in patients with T2 DM.